Targets › FCGR2B
4 programs from 4 companies in 10 trials: 6 Phase 2, 2 Phase 3, 2 Phase 1; Neurology, Other, Hematology; next expected readout Dec 2026.
Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. (UniProt, P31994)
Open in Phaseline: the race on FCGR2B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zenas BioPharma (USA) | Obexelimab B-lymphocyte antigen CD19 inhibitor; Low affinity immunoglobulin gamma Fc region receptor II-b inhibitor | CD19, FCGR2B | Phase 3 | Warm Autoimmune Hemolytic Anemia; IgG4 Related Disease; Relapsing Multiple Sclerosis; Systemic Lupus Erythematosus | Dec 2026 |
| Nuvig Therapeutics | NVG-2089 FcγRIIB agonist (IVIg mimetic) | FCGR2B | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy; Immune Thrombocytopenia (ITP) | Jun 2027 |
| argenx | ARGX-117 FcγRIIB agonist / IgG4-Fc fusion protein | FCGR2B | Phase 2 | Multifocal Motor Neuropathy (MMN); Delayed Graft Function | Sep 2029 |
| BioInvent International | BI-1206 anti-CD32B monoclonal antibody | FCGR2B | Phase 1 | Indolent B-Cell Non-Hodgkin Lymphoma; Solid Tumor, Adult | Sep 2027 |
Multifocal Motor Neuropathy (MMN) (1) Delayed Graft Function (1) Chronic Inflammatory Demyelinating Polyneuropathy (1) Immune Thrombocytopenia (ITP) (1) Warm Autoimmune Hemolytic Anemia (1) IgG4 Related Disease (1) Relapsing Multiple Sclerosis (1) Systemic Lupus Erythematosus (1) Indolent B-Cell Non-Hodgkin Lymphoma (1) Solid Tumor, Adult (1)
antibody (2), protein or peptide (1), small molecule (1)
argenx (1) Nuvig Therapeutics (1) Zenas BioPharma (USA) (1) BioInvent International (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.